secwatch.observer — SEC 8-K summary
======================================

Issuer:     BNB PLUS CORP. (BNBX)
CIK:        0000744452
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001104659-24-087280
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Applied DNA Sciences Q3 FY2024 revenue falls 72% YoY to $798K; operating loss widens
--------------------------------------------------------------------------------

- Total revenues $798K for Q3 ended June 30, 2024, down from $2.9M, driven by end of CUNY COVID testing contract.
- Gross profit $245K (31% margin) vs $1.3M (44%); operating loss $3.3M vs $2.9M year ago.
- Adjusted EBITDA negative $3.2M vs negative $2.1M; cash position $10.4M up from $7.2M after $10.5M public offering.
- LineaRx GMP facility on track for FY24 year-end launch; Linea IVT GMP runs expected early CY25.
- Multi-year certainT agreement with Indus Group post-close; TR8 PGx testing capacity set at potential $25M annual revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744452/000110465924087280/0001104659-24-087280-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744452/000110465924087280/tm2421159d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-087280

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer